Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Samsung BioLogics and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy.
read more
Wednesday, March 04, 2020
Samsung Biologics and STCube announced a strategic development and manufacturing service agreement for STT-003 antibody, an anti-cancer drug candidate.
read more
Wednesday, February 17, 2021
Samsung Biologics announced IND clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy.
read more
Monday, November 11, 2019
Samsung Biologics announced the signing of a long-term agreement with Ichnos Sciences for manufacturing drug substance for ISB 830.
read more
Tuesday, October 11, 2022
Samsung Biologics announced that its Plant 4 has commenced GMP operations this month.
Plant 4's partial operations comes just 23 months after construction began in November 2020, adding fresh production capacity of 60,000 liters.
read more
Samsung Biologics announced plans to add mRNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022. mRNA has been the technology of choice for ...
read more
Monday, September 28, 2020
Samsung Biologics has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors.
read more
Samsung BioLogics and GI Innovation have signed a Contract Development Organization (CDO) contract for immunochemotherapy.
read more
Thursday, January 12, 2023
Samsung Biologics, a leading contract development and manufacturing organization (CDMO), was awarded the Sustainable Markets Initiative’s Terra Carta Seal.
read more
Wednesday, December 13, 2017
Samsung BioLogics has been licensed by the Europe’s EMA for the first monoclonal antibody Drug Substance at its second plant.
read more
Samsung Biologics announced that the company was awarded the EcoVadis' Platinum Sustainability Rating, the highest recognition given, for the company's sustainability management.
read more
Samsung BioLogics announced today that a third monoclonal antibody Drug Substance has been licensed by the FDA for its second plant.
read more
Samsung Biologics signed an agreement with the Incheon Free Economic Zone (IFEZ) on July 18th to build out its second Bio Campus.
read more
Samsung BioLogics announced on October 1st, 2018 that its Plant 3 has become cGMP ready and started production (OOF, out of freezing) after its successful validation.
read more
Samsung Biologics has successfully renewed its ISO 27001 certification (Information Security Management System) and obtained ISO 27017 certification (Information Security in cloud services) and ISO 37001 certification (Anti-bribery management systems...
read more